comparemela.com
Home
Live Updates
Mirikizumab Offers Durable Response Up to 2 Years in UC : comparemela.com
Mirikizumab Offers Durable Response Up to 2 Years in UC
A long-term maintenance study suggested continuing mirikizumab for 104 weeks is safe and provides durable benefit in patients with active ulcerative colitis.
Related Keywords
New York ,
United States ,
Brucee Sands ,
,
Icahn School Of Medicine ,
Inflammatory Bowel Disease Questionnaire ,
Icahn School ,
Mount Sinai ,
New York City ,
Inflammatory Bowel ,
comparemela.com © 2020. All Rights Reserved.